Who is sponsoring NCT06711471?

NCT06711471 is sponsored by LIN YANG.

What condition does NCT06711471 study?

NCT06711471 studies Gastric Cancer Adenocarcinoma Metastatic.

Is NCT06711471 still recruiting?

NCT06711471 is currently recruiting now. Last updated 2 December 2024.

Last reviewed 2024-12-02 · How we verify

NCT06711471

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

Recruiting now Phase 2 Last updated 2 December 2024

What this trial tests

Phase 2 trial testing trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab in Gastric Cancer Adenocarcinoma Metastatic in 31 participants. Currently enrolling.

Timeline

14 November 2024

Primary endpoint
13 November 2026

13 November 2027

Quick facts

Lead sponsor	LIN YANG
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	14 November 2024
Primary completion	13 November 2026
Estimated completion	13 November 2027
Sites	1 location across China

Drugs / interventions tested

trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab — full drug profile →

Conditions studied

Gastric Cancer Adenocarcinoma Metastatic — all drugs for Gastric Cancer Adenocarcinoma Metastatic →

Sponsor

LIN YANG — full company profile →

Who can join

18 and older, any sex, with Gastric Cancer Adenocarcinoma Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

For patients with metastatic gastric cancer, the efficacy of current standard treatments outlined in the guidelines is far from meeting the clinical demand. This study aims to explore the efficacy and safety of trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab as a novel third-line or later-line therapy for metastatic gastric cancer patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gastric Cancer Adenocarcinoma Metastatic

Currently open trials in the same condition.

NCT06962137 — Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer · Phase 2 · recruiting
NCT07392346 — Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Tr · Phase 2 · recruiting
NCT07149090 — Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites · Phase 1, PHASE2 · recruiting
NCT06702683 — The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced G · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06711471 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LIN YANG
Last refreshed: 2 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06711471.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing